IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by KBC Group NV

KBC Group NV raised its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 29.1% during the third quarter, HoldingsChannel reports. The firm owned 2,274 shares of the company’s stock after buying an additional 513 shares during the period. KBC Group NV’s holdings in IDEAYA Biosciences were worth $72,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in IDYA. Allworth Financial LP increased its position in IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the period. Covestor Ltd grew its stake in shares of IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after purchasing an additional 922 shares during the last quarter. Quest Partners LLC acquired a new position in shares of IDEAYA Biosciences in the second quarter valued at approximately $41,000. US Bancorp DE raised its stake in shares of IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Comerica Bank lifted its holdings in shares of IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after purchasing an additional 1,324 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $26.79 on Friday. IDEAYA Biosciences, Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $47.74. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 0.86. The stock’s fifty day moving average is $30.39 and its two-hundred day moving average is $35.82.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter last year, the firm earned ($0.46) earnings per share. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Stifel Nicolaus raised their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. UBS Group assumed coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 target price on the stock. Finally, Oppenheimer reissued an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.